Building the Next Generation of Respiratory Challenge Models

Advancing Respiratory Challenge Models From RSV to hMPV: Building the Next Generation of Respiratory Challenge Models

Respiratory viruses such as RSV and hMPV present persistent challenges for drug and vaccine developers. Controlled human infection models are transforming how these pathogens are studied, enabling faster, more predictive clinical development.

This article explores how next-generation respiratory challenge models are shaping the future of infectious disease research, including:

Why RSV and hMPV remain high-priority respiratory targets
The role of CHIMs in improving translational confidence
How challenge models accelerate early-phase clinical development
Key considerations when selecting respiratory challenge studies
Implications for vaccines, antivirals, and immunomodulators